The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Correction (v148,p819)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Carpenter, W. T.
* Articles by Buchanan, R. W.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Carpenter, W. T., Jr
* Articles by Buchanan, R. W.

Am J Psychiatry 1990; 147:1138-1148
Copyright © 1990 by American Psychiatric Association


BRIEF REPORTS

Continuous versus targeted medication in schizophrenic outpatients: outcome results [published erratum appears in Am J Psychiatry 1991 Jun;148(6):819]

WT Carpenter Jr, TE Hanlon, DW Heinrichs, AT Summerfelt, B Kirkpatrick, J Levine and RW Buchanan
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228.

The authors report on the outcome of treatment of 116 outpatients with chronic schizophrenia who were assigned to a 2-year, single-blind course of treatment with either targeted or continuous medication. These patients were not restricted to those who were good candidates for a medication reduction strategy. Continuous medication was superior to targeted medication in preventing decompensations and hospitalizations and in extent of employment at 2 years. Other measures of psychopathology and functioning at 1 and 2 years did not differentiate the two groups of patients. The targeted approach achieved a substantial reduction in total medication through a reduction in the number of days of medication administration.


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
M. S Turner and D. W Stewart
Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
J Psychopharmacol, November 1, 2006; 20(6 Suppl): 20 - 37.
[Abstract] [PDF]


Home page
Psychiatr. Serv.Home page
S. J. Keith, L. Pani, B. Nick, R. Emsley, L. San, M. Turner, R. Conley, P. Scully, P. S. Chue, and B. Lachaux
Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia
Psychiatr Serv, September 1, 2004; 55(9): 997 - 1005.
[Abstract] [Full Text] [PDF]


Home page
FocusHome page
M. Gitlin, K. Nuechterlein, K. L. Subotnik, J. Ventura, J. Mintz, D. L. Fogelson, G. Bartzokis, and M. Aravagiri
Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia
Focus, January 1, 2004; 2(1): 122 - 130.
[Abstract] [Full Text] [PDF]


Home page
FocusHome page
N. R. Schooler
Maintenance Medication for Schizophrenia: Strategies for Dose Reduction
Focus, January 1, 2004; 2(1): 175 - 186.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Bull.Home page
S. O'Ceallaigh and T. Fahy
Is there a role for the depot clinic in the modern management of schizophrenia?
Psychiatr. Bull., December 1, 2001; 25(12): 481 - 484.
[Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
M. Gitlin, K. Nuechterlein, K. L. Subotnik, J. Ventura, J. Mintz, D. L. Fogelson, G. Bartzokis, and M. Aravagiri
Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia
Am J Psychiatry, November 1, 2001; 158(11): 1835 - 1842.
[Abstract] [Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
M. Birchwood, E. Spencer, and D. McGovern
Schizophrenia: early warning signs
Advan. Psychiatr. Treat., March 1, 2000; 6(2): 93 - 101.
[Full Text]


Home page
Arch Gen PsychiatryHome page
M. I. Herz, J. S. Lamberti, J. Mintz, R. Scott, S. P. O'Dell, L. McCartan, and G. Nix
A Program for Relapse Prevention in Schizophrenia: A Controlled Study
Arch Gen Psychiatry, March 1, 2000; 57(3): 277 - 283.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
W. T. Carpenter Jr., R. W. Buchanan, B. Kirkpatrick, H. D. Lann, A. F. Breier, and A. T. Summerfelt
Comparative Effectiveness of Fluphenazine Decanoate Injections Every 2 Weeks Versus Every 6 Weeks
Am J Psychiatry, March 1, 1999; 156(3): 412 - 418.
[Abstract] [Full Text]


Home page
Am. J. PsychiatryHome page
W. T. Carpenter Jr., R. W. Buchanan, B. Kirkpatrick, and A. F. Breier
Diazepam Treatment of Early Signs of Exacerbation in Schizophrenia
Am J Psychiatry, February 1, 1999; 156(2): 299 - 303.
[Abstract] [Full Text]


Home page
NEJMHome page
J. M. Kane
Schizophrenia
N. Engl. J. Med., January 4, 1996; 334(1): 34 - 42.
[Full Text] [PDF]


Home page
DTBHome page
The drug treatment of patients with schizophrenia
DTB, November 1, 1995; 33(11): 81 - 86.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. T. Carpenter and R. W. Buchanan
Schizophrenia
N. Engl. J. Med., March 10, 1994; 330(10): 681 - 690.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 1990 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org